ZOL446 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 274 | Osteogenesis Imperfecta | 3 |
274. Osteogenesis Imperfecta
Clinical trials : 91 / Drugs : 101 - (DrugBank : 20) / Drug target genes : 11 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-001666-40-GB (EUCTR) | 14/06/2005 | 13/05/2005 | An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E | An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E | Osteogenesis Imperfecta | Product Name: zoledronic acid Product Code: ZOL446 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 130 | Hungary;United Kingdom | |||
| 2 | EUCTR2004-001666-40-HU (EUCTR) | 01/02/2005 | 25/11/2004 | An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E | An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E | Osteogenesis Imperfecta | Product Name: zoledronic acid Product Code: ZOL446 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 130 | Hungary;United Kingdom | |||
| 3 | EUCTR2004-001666-40-BE (EUCTR) | 05/09/2005 | An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E | An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E | Osteogenesis Imperfecta | Product Name: zoledronic acid Product Code: ZOL446 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 130 | Phase 2 | Hungary;Belgium;United Kingdom |